Predictors of Outcomes Following Transcatheter Edge-to-Edge Mitral Valve Repair.
Ben-Shoshan JMcGill University Health Center, McGill University, Montreal, Quebec, Canada; Tel-Aviv Medical Center, Tel-Aviv University, Tel-Aviv, Israel.
Overtchook PMcGill University Health Center, McGill University, Montreal, Quebec, Canada; Bern University Hospital, University of Bern, Bern, Switzerland.
Buithieu JMcGill University Health Center, McGill University, Montreal, Quebec, Canada.
Mousavi NMcGill University Health Center, McGill University, Montreal, Quebec, Canada.
Martucci GMcGill University Health Center, McGill University, Montreal, Quebec, Canada.
Spaziano MMcGill University Health Center, McGill University, Montreal, Quebec, Canada.
de Varennes BMcGill University Health Center, McGill University, Montreal, Quebec, Canada.
Lachapelle KMcGill University Health Center, McGill University, Montreal, Quebec, Canada.
Brophy JMcGill University Health Center, McGill University, Montreal, Quebec, Canada.
Modine TCentre Hospitalier Regional et Universitaire de Lille, Lille, France.
Baumbach ABarts Heart Centre, Barts Health NHS, Queen Mary University, London, United Kingdom.
Maisano FUniversity Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Prendergast BSt. Thomas' Hospital, London, United Kingdom.
Tamburino CFerrarotto Hospital, University of Catania, Catania, Italy.
Windecker SBern University Hospital, University of Bern, Bern, Switzerland.
Piazza NMcGill University Health Center, McGill University, Montreal, Quebec, Canada. Electronic address: nicolopiazza@mac.com.
English
Transcatheter edge-to-edge mitral valve repair is a viable alternative to surgery in patients with severe mitral regurgitation and high surgical risk. Yet the specific group of patients who would optimally benefit from this therapy remains to be determined. Selection of patients for transcatheter strategy is currently based on surgical prognostic scores and technical feasibility. Meanwhile, various clinical, anatomic, and procedural factors have been recently recognized as predictors of adverse outcomes following transcatheter edge-to-edge mitral valve repair, including device failure, recurrent mitral regurgitation, and mortality. Integration of these prognostic factors in the decision-making process of the heart team might improve patient management and outcomes. Herein, the authors review the different factors related to symptomatic status, comorbidity, serum biomarkers, echocardiographic findings, and procedural technique that have been identified as independent predictors of adverse outcome following transcatheter edge-to-edge mitral valve repair and discuss their potential application in everyday clinical practice.